Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen

LONDON, September 4, 2014 /PRNewswire/ --

On Wednesday, September 03, 2014, the NASDAQ Composite ended at 4,572.57, down 0.56%, the Dow Jones Industrial Average finished the day 0.06% higher at 17,078.28, and the S&P 500 closed at 2,000.72, down 0.08%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 740.75, up 0.41%, with the index advancing 6.93% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Arrowhead Research Corporation (NASDAQ: ARWR), Celgene Corporation (NASDAQ: CELG), and Amgen Inc. (NASDAQ: AMGN). Free research on these five companies can be accessed at:  

http://investor-edge.com/register

ARIAD Pharmaceuticals Inc.'s stock finished Wednesday's session 1.76% lower at $6.14. A total of 3.19 million shares were traded, which was much below its three months average volume of 8.07 million shares. The stock vacillated between $6.14 and $6.32 during the session. Over the last one month, ARIAD Pharmaceuticals Inc.'s shares have gained 9.45%. However, the stock has fallen by 8.22% over the previous three months and 9.97% from the beginning of 2014. The company's shares are trading above their 50-day moving average. Moreover, the stock's 200-day moving average of $6.57 is greater than its 50-day moving average of $5.92. ARIAD Pharmaceuticals Inc.'s stock has a Relative Strength Index (RSI) of 57.31. Sign up and read the free notes on ARIA at:

www.Investor-Edge.com/ARIA-04Sep2014

On Wednesday, shares in Tekmira Pharmaceuticals Corp. fluctuated between $18.65 and $20.25 before ending the session 4.42% lower at $19.23. The stock reported a trading volume of 2.45 million shares, close to its three months average volume of 2.64 million shares. Tekmira Pharmaceuticals Corp.'s shares have rallied 34.85% in the last one month, 64.50% in the previous three months, and 141.28% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $14.30 and $14.38, respectively. Moreover, shares of Tekmira Pharmaceuticals Corp. have an RSI of 59.97. The complimentary notes on TKMR can be downloaded as in PDF format at:

www.Investor-Edge.com/TKMR-04Sep2014

Arrowhead Research Corp.'s stock rallied 6.06%, to close the day at $16.27. The stock recorded a trading volume of 7.84 million shares, much above its three months average volume of 2.93 million shares. The company's shares oscillated between $15.61 and $17.38 during the session. Over the last three trading sessions and over the past one month, Arrowhead Research Corp.'s shares have surged 15.06% and 35.81%, respectively. Further, the stock has gained an upside of 49.95% since the start of this year. The company's stock is trading above its 50-day and 200-day moving averages. Arrowhead Research Corp.'s 200-day moving average of $13.67 is above its 50-day moving average of $12.90. Additionally, the stock and has an RSI of 61.87. Register for free on Investor-Edge and access the latest research on ARWR at:

www.Investor-Edge.com/ARWR-04Sep2014

On Wednesday, shares in Celgene Corp. recorded a trading volume of 2.61 million shares, lower than its three months average volume of 4.50 million shares. The stock ended the day at $94.94, which was 0.16% below its previous day's closing of $95.09, and registered an intraday range of $94.50 and $95.89. Shares of the company traded at a PE ratio of 38.51. Celgene Corp.'s stock has advanced 0.25% in the previous three trading sessions, 9.57% in the last one month, and 12.38% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $88.49 and $80.69, respectively. Furthermore, shares of Celgene Corp. have an RSI of 70.87. The complete research on CELG is available for free at:

www.Investor-Edge.com/CELG-04Sep2014

Amgen Inc.'s stock edged 0.45% higher to end Wednesday's session at $138.58. The stock recorded a trading volume of 2.73 million shares, below its three months average volume of 3.01 million shares. The company's shares fluctuated between $137.34 and $138.85 during the session. Shares of the company traded at a PE ratio of 20.73. Amgen Inc.'s shares have gained 21.48% since the start of this year. Further, the stock has advanced 10.38% in the last one month and 18.32% over the previous three months. The company's stock is trading above its 50-day and 200-day moving averages. Amgen Inc.'s 50-day moving average of $125.43 is above its 200-day moving average of $119.44. Additionally, the stock has an RSI of 71.83. Free in depth research on AMGN is available at:

www.Investor-Edge.com/AMGN-04Sep2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED